Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Identification of exosomes in non-Hodgkin B-cell lymphomas. Prognostic usefulness in patients treated with rituximab-chemotherapy: a prospective, multicenter correlation study by the Spanish Lymphoma Oncology Group (GOTEL)

Date

08 Oct 2016

Session

Poster Display

Presenters

Mariano Provencio

Citation

Annals of Oncology (2016) 27 (6): 313-327. 10.1093/annonc/mdw375

Authors

M. Provencio1, M. Rodriguez-Balada2, B. Cantos3, C. Quero4, R. García Arroyo5, A. Rueda6, C. Maximiano3, D. Rodriguez Abreu7, A. Sanchez8, V. Garcia8

Author affiliations

  • 1 Medical Oncology, Hospital Universitario Puerta de Hierro Majadahond, 28222 - Majadahonda/ES
  • 2 Pathology, University Hospital St. Joan de Reus, Reus/ES
  • 3 Medical Oncology, Hospital Universitario Puerta de Hierro, 28222 - Madrid/ES
  • 4 Medical Oncology, Hospital Universitario Virgen de la Victoria, Malaga/ES
  • 5 Medical Oncology, Complejo Hospitalario de Pontevedra, 36004 - Pontevedra/ES
  • 6 Medical Oncology, Hospital Costa del Sol, 29602 - Malaga/ES
  • 7 Medcal Oncology Service, Hospital Universitario Insular de Gran Canaria, 35016 - Las Palmas/ES
  • 8 Medical Oncology, Hospital Universitario Puerta de Hierro, Madrid/ES
More

Resources

Background

To determine the presence of mRNAs (C-MYC, BCL-XL, BCL-6, NF-κß, PTEN and AKT) in exosomes of plasma from patients with B-Cell Lymphoma, and its relationship with their response to rituximab-based chemotherapy and survival.

Methods

Exosomes were isolated of 98 patients with B-cell Lymphoma and 68 healthy controls. mRNAs were analyzed by quantitative PCR. 31 post-treatment samples were also studied.

Results

Exosome levels were not associated with response to treatment and outcome of patients. In general series and follicular lymphomas (FL), presence of AKT mRNA was associated with non-response to rituximab-based treatment. Patients with first relapse or disease progression showed a lower percentage of presence of PTEN and BCL-XL mRNA. Presence of BCL-6 mRNA was associated with high rate of death of patients. Absence of PTEN mRNA, in general series, and presence of C-MYC mRNA, in FL, was associated with short Progression-Free Survival. BCL-6 and C-MYC mRNA were independent prognostic variables for OS. C-MYCmRNA interacted with response to treatment, giving prognostic value for OS in non responsive patients. In post-treatment samples, presence of BCL-XL mRNA was associated with high rate of death; and appearance of BCL-6 mRNA and loss of PTENmRNA were associated with non-response to treatment.

Conclusions

It is possible to identify exosomes in plasma of lymphoma patients. This may assist in prognosis, both at the start of treatment and during follow-up, and in identification of those patients at greater risk of progression. In both situations, the presence of BCL-6 identifies the patients with worse prognosis.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

Spanish Lymphoma Oncology Group (GOTEL).

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings